ATLASUroGen Pharma (URGN) earnings date: Nov 4, 2026
UroGen Pharma (URGN) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 4, 2026, before the open. Analysts expect EPS of $0.05.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on URGN
| Last price | $34.32 (+4.9%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.9% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 6 reports |
These figures come from the same calibrated model and valuation as the UroGen Pharma stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
UroGen Pharma reports on Nov 4, 2026. One email the day before, with ATLAS’s read on UroGen Pharma. You can switch it off at any time.
Alert me before URGN reportsFree to start. Creating an account takes under a minute.
Notify me when UroGen Pharma reports
Track URGN free Add UroGen Pharma to a free ATLAS watchlist and see its next report date in one place.
URGN earnings at a glance
| Next report (confirmed) | Wed, Nov 4, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | $0.05 |
| Last report | Oct 9, 2026 · Beat |
| Beat rate (last 6 reports) | 4 of 6 (67%) |
| Average EPS surprise | +10.1% |
| Average move around a report | ±8.8% (last 6) |
| Sector | Healthcare · Biotechnology |
UroGen Pharma earnings history: last 6 reports
UroGen Pharma last reported on Oct 9, 2026: EPS of -$0.06 against an estimate of -$0.12 (+50.0% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Oct 9, 2026 | -$0.12 | -$0.06 | +50.0% | Beat | +3.6% |
| Aug 5, 2026 | -$0.26 | -$0.28 | -7.7% | Miss | +14.2% |
| May 6, 2026 | -$0.48 | -$0.47 | +2.1% | Beat | +11.6% |
| Mar 2, 2026 | -$0.51 | -$0.53 | -3.9% | Miss | -13.3% |
| Feb 12, 2026 | $1.03 | $1.07 | +3.9% | Beat | -4.9% |
| Jan 23, 2026 | $1.61 | $1.87 | +16.2% | Beat | +5.4% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for URGN
See the fair value, the probability range and the earnings history of UroGen Pharma on its ATLAS page.
UroGen Pharma (URGN) stock analysisPlans from €3.99 a month.
UroGen Pharma earnings: frequently asked questions
When does UroGen Pharma (URGN) report earnings?
UroGen Pharma is scheduled to report on Wednesday, November 4, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for URGN?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is $0.05 per share (USD). Estimates can change before the report.
How often does URGN beat earnings estimates?
Of its last 6 reports with a recorded result, UroGen Pharma beat the EPS estimate 4 times; the average surprise was +10.1%. Past results do not predict the next one.
How much does URGN move around earnings?
Over its last 6 reports the stock moved an average of 8.8% (absolute, from the close before the report day to the close after it), and finished higher 4 of 6 times.
Did UroGen Pharma beat earnings estimates last quarter?
UroGen Pharma last reported on Oct 9, 2026: EPS of -$0.06 against an estimate of -$0.12 (+50.0% surprise), a beat.
How much does URGN usually move in a day?
On a normal trading day the ATLAS model puts URGN’s one-day range at about ±2.9%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 4, 2026
Educational information, not investment advice. Disclaimer